Search Results

November 12, 2012

New Phase 3 Findings Show STELARA® Significantly Reduced Signs And Symptoms Of Active Psoriatic Arthritis

STELARA Continued to Provide Benefit in Psoriatic Arthritis Signs and Symptomsthrough Week 52 in One Phase 3 Trial

November 12, 2012

Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis

Patients Receiving Intravenous Golimumab Showed Significant Improvements inSigns and Symptoms of Rheumatoid Arthritis through One Year According to New Study Findings

Corporate

November 12, 2012

Johnson & Johnson Family of Diabetes Companies Provides Diabetes Supplies to Children in Developing Countries

LifeScan, Inc. supplies one million test strips and encourages support for International Diabetes Federation’s Life for a Child program

Innovative Medicine

November 9, 2012

Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes

Innovative Medicine

November 9, 2012

FDA Approves New 800mg PREZISTA® (darunavir) Tablet

Innovative Medicine

November 5, 2012

Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (Tmc435) And Vx-135 For Treatment Of Hepatitis C

Innovative Medicine

November 2, 2012

FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events

XARELTO® Has the Broadest Indication Profile of Any New Oral Anticoagulant

Innovative Medicine

October 22, 2012

New One-Year Phase 3 Study Results Show Anti-Tnf SIMPONI® Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis

Data Demonstrate Remission and Mucosal Healing with SIMPONI Maintenance Therapy

Innovative Medicine

October 18, 2012

Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA® Treatment

STELARA Phase 2b Crohn’s Disease Study Published in The New England Journal of Medicine

Innovative Medicine

October 2, 2012

First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease

Canagliflozin also shown effective and generally well-tolerated in patients with type 2 diabetes aged 55 to 80 in separate Phase 3 study

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine